Notice2024-07278
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
April 5, 2024
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. to achieve expeditious commercialization of results of federally-funded research and development.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 67 (Friday, April 5, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 67 (Friday, April 5, 2024)]
[Notices]
[Page 24023]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-07278]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. to achieve
expeditious commercialization of results of federally-funded research
and development.
FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained
by contacting Michael Shmilovich, Esq, MS, CLP; 301-435-5019;
<a href="/cdn-cgi/l/email-protection#92fffbf1faf3f7febce1fafffbfefde4fbf1fad2fcfbfabcf5fde4"><span class="__cf_email__" data-cfemail="630e0a000b02060f4d100b0e0a0f0c150a000b230d0a0b4d040c15">[email protected]</span></a>, at the National Heart, Lung, and Blood,
Office of Technology Transfer and Development Office of Technology
Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479.
A signed Confidential Disclosure Agreement may be required to receive
any unpublished information.
SUPPLEMENTARY INFORMATION: This notice is in accordance with 35 U.S.C.
209 and 37 CFR part 404. Technology description follows. Prazole-Based
Antiviral Therapeutics:
Available for licensing and commercial development is a patent
estate that covers prazole based compounds and their methods of use as
antiviral therapeutics. Prazoles are benzimidazole derivatives
generally marketed as stomach-acid reducers, owing to their ability to
inhibit the H+/K+ ATPases (proton pumps) of the parietal cells in the
stomach epithelium. Prazoles can inhibit the egress of several viral
targets: HIV-1, HSV-1 and -2, MAYV, and EBV by interfering with the
ESCRT complex in the formation of exosomes. In that respect, the target
for inhibition of these viruses is Tumor susceptibility gene 101
(Tsg101), a member of the ESCRT-I complex. The N-terminal ubiquitin E2
variant (UEV) domain of Tsg101 has both ubiquitin and P[T/S]AP motif
binding sites, where the prazole binds to C73 in the middle of the
ubiquitin-binding site, sterically inhibiting the Ub-Tsg101
interaction. By way of example, and not limitation, a prazole compound
according to this invention can take on the follow core structure:
[GRAPHIC] [TIFF OMITTED] TN05AP24.048
Where L is optionally present and is a C<INF>1</INF>-C<INF>6</INF>
alkyl group, a C<INF>1</INF>-C<INF>6</INF> alkoxy group, a -
(CH<INF>2</INF>CH<INF>2</INF>O)<INF>n</INF>- group where n is an
integer from 1 to 6, a phenyl group, or a benzyl group, each of which
is optionally substituted. B is a substituted or unsubstituted aromatic
or heteroaromatic substituent, and where
X<INF>1</INF> is S(=O) or S;
Y<INF>1</INF> is N or CR<INF>4</INF>; and
each of R<INF>1</INF>-R<INF>7</INF> is independently selected from
hydrogen, C<INF>1</INF>-C<INF>6</INF> alkyl, C<INF>1</INF>-
C<INF>6</INF> alkoxy, perfluoro C<INF>1</INF>-C<INF>6</INF> alkyl,
perfluoro C<INF>1</INF>-C<INF>6</INF> alkoxy, halo, -CN, -OH, -
COOR<INF>8</INF>, substituted or unsubstituted aromatic, or
substituted or unsubstituted heteroaromatic, and
each R<INF>8</INF> independently is hydrogen, C<INF>1</INF>-
C<INF>6</INF> alkyl, phenyl, or benzyl.
Potential Commercial Applications:
<bullet> antivirals
<bullet> therapeutics
<bullet> ESCRT complex formation
<bullet> prazole
<bullet> antifungal
Development Stage:
<bullet> Early stage
Inventors: Nico Tjandra (NHLBI), Carol Carter (Stonybrook), Rolf E.
Swenson (NHLBI), David Nyenhuis (NHLBI), Natarajan Raju (NHLBI),
Chandra Mushti, (NHLBI), and Venkata Sabbasani (NHLBI).
Intellectual Property: HHS Reference No. E-239-2023-0; U.S.
Provisional Patent Application No. 63/545,080 filed October 20, 2023.
Publication: D. A. Nyenhuis, S. Watanabe, R. Bernstein, R. E.
Swenson, N. Raju, V. R. Sabbasani, C. Mushti, D.-Y. Lee, C. Carter, N.
Tjandra, ``Structural Relationships to Efficacy for Prazole-Derived
Antivirals.'' Adv. Sci. 2024, 2308312. <a href="https://doi.org/10.1002/advs.202308312">https://doi.org/10.1002/advs.202308312</a>.
Licensing Contact: Michael Shmilovich, Esq, MS, CLP; 301-435-5019;
<a href="/cdn-cgi/l/email-protection#bfd2d6dcd7dedad391ccd7d2d6d3d0c9d6dcd7ffd1d6d791d8d0c9"><span class="__cf_email__" data-cfemail="7815111b10191d14560b10151114170e111b1038161110561f170e">[email protected]</span></a>.
Dated: April 2, 2024.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood
Institute, Office of Technology Transfer and Development.
[FR Doc. 2024-07278 Filed 4-4-24; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on April 5, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.